Difference between revisions of "Tirabrutinib (Velexbru)"
Jump to navigation
Jump to search
m |
m |
||
| Line 19: | Line 19: | ||
[[Category:CNS lymphoma medications]] | [[Category:CNS lymphoma medications]] | ||
[[Category:Waldenström macroglobulinemia medications]] | [[Category:Waldenström macroglobulinemia medications]] | ||
| − | [[Category:PMDA approved | + | [[Category:PMDA approved in 2020]] |
Revision as of 16:54, 8 June 2023
Mechanism of action
BTK inhibitor
Diseases for which it is used
History of changes in PMDA indication
- 2020-03-25: Newly indicated for the treatment of relapsed or refractory primary central nervous system (CNS) lymphoma.
- 2020-08-21: new indications for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma.
Also known as
- Code name: GS-4059
- Brand name: Velexbru